Centella asiatica extract
As of the edition of 20 October 2026, Centella asiatica extract is a drug: marketed, first approved in 1961 (ES).
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 1996
- Kind
- Unknown
- Brand name
- Blastoestimulina
- First approved
- 1 April 1961 (ES)
- Approvals on record
- 3 in 3 regions
- Holder of the most recent approval
- Bayer; 3 holders in all
- Registered trials
- 54, 2 stopped early
- Disease areas
- Cancer; Digestive system; Hormones; Lungs and airways; Nervous system; Injuries
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 2 | 0 | 0 | 0 |
| Phase 1 | 4 | 2 | 1 | 1 |
| Phase 2 | 42 | 8 | 9 | 1 |
| Phase 3 | 4 | 1 | 1 | 0 |
| Phase 4 | 2 | 0 | 0 | 0 |
| All trials | 54 |